Drug Approvals
Merck Is Hot. Red Hot. Here's Why
Merck has had a very busy week -- and investment dollars have followed.
3 Small Biotechs With Favorable Risk Vs. Reward Profiles
BioDelivery Sciences International, Chiasma Inc. and TherapeticsMD all feature promising treatments.
Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation
Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.
Checking In on 2 Small Biotech Names That Had Big Quarters
Stemline Therapeutics and Flexion Therapeutics both saw their shares climb on positive news developments.
2 Promising $5 Biotech Stocks to Consider on Recent News
Jounce Therapeutics and Ocular Therapeutix each provided investors with positive news morsels last week.
Mylan Jumps on Deal With Pfizer to Form New Company
Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.
Watch These 4 Japanese Drugmakers With Big Coming Events
Investors should keep tabs on these "focus events" from this quartet of U.S.-listed Japanese drugmakers that can make or break their treatments.
2 Attractive Biotechs With Key Study Outcomes on the Horizon
Intra-Cellular Therapies and Acadia Pharmaceuticals are worth investors' attention.
IPO Gives Chinese Couple a 'Hansoh' Sum
The initial public offering of Hansoh Pharmaceutical Group made the Chinese couple Zhong Huijuan and Sun Piaoyang the richest in the nation.
Jim Cramer: A Tale of Two Stocks
I want you to remember Eli Lilly and Johnson & Johnson the next time you are about to dump a stock because of some bits of bad news.